THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Belluscura plc

("Belluscura" or the "Company" or "Group")

 Belluscura Signs Distribution Agreement with Subsidiary of World's Largest Drug Distributor

McKesson Medical-Surgical Corporation expands its respiratory offerings by entering into a distribution agreement with Belluscura

LONDON, U.K. AND PLANO, TX, U.S. (01 August 2023). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that it has signed a distribution agreement with McKesson Medical-Surgical, a division of McKesson, the 9^th largest company by revenue in the US. McKesson delivers a third of all pharmaceuticals used in North America and operates the fourth-largest pharmacy chain in North America.

The X-PLOR® portable oxygen concentrator will now be available to McKesson's customers through their online catalogue.

Robert Fary. Sr Vice President of Global Sales, Belluscura plc, commented:

"We continue to expand the distribution of the X-PLOR throughout the US and this exciting agreement will extend our reach to patients seeking access to best-in-class devices." 

Robert Rauker, Chief Executive Officer, Belluscura plc, commented:

"We are very pleased that McKesson, one of the largest distributors of pharmaceuticals and medical devices in North America, has chosen the X-PLOR to be offered through their catalogue. This significant distribution agreement will mean that more Americans can purchase our devices throughout the country, broadening our product distribution and making supplemental oxygen more easily accessible."

For further information please contact:

About Belluscura plc (www.belluscura.com)

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.